Role of BTK-inhibitors in B-cell malignancies
Prof. Stephan Stilgenbauer, hematologist at the Ulm University in Germany shares his view on the role of BTK-inhibitors in B-cell malignancies. He discusses the potential of second-generation BTK-inhibitors and provides insight into selecting the right treatment for the right patient among the various newly available treatments for CLL patients.
With the educational support of:
